About Vyriad
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated.
Phase 1-2 trials with our oncolytic viruses, as monotherapies or in combination with immuno-oncology drugs, are underway in multiple cancer indications in collaboration with Regeneron, Mayo Clinic, Merck KGaA/Pfizer and other leading research and medical institutions.
News and Events
September 13, 2022
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
Meet Vyriad
Our Technology
At Vyriad, we harness the natural cell killing ability of viruses to turn them into effective anticancer drugs. Through genetic modification, we program viruses to better target and infect cancer cells, deliver powerful therapeutic payloads, and mobilize the immune system. These oncolytic viruses do not harm normal cells, pose no risk of transmission to the population, and can generate immunological memory to protect against cancer recurrence. Vyriad has two potent viral platforms with natural characteristics that are ideal for creating a generation of safe, trackable and effective oncolytic viruses. We believe our best-in-class oncolytic viral platforms will become a backbone therapy for numerous cancers and ultimately may provide patients with a single shot cure. Click here to learn about our oncolytic viruses.
VSV Platform
Powerful, Robust & Flexible
Vesicular Stomatitis Virus (VSV) is a potent, rapidly replicating virus with the ability to target, infect and kill cancer cells after intravenous delivery. Vyriad has developed proprietary technology to rapidly engineer VSV to boost its anticancer activity, and to allow noninvasive monitoring in patients. In partnership with Regeneron Pharmaceuticals, we will evaluate a Voyager-V1 combination therapy in the clinic and jointly design and validate a new generation of precision targeted VSV therapies.
Learn MoreMV Platform
Fusogenic, Immunogenic & Programmable
Measles Virus (MV) possesses natural anti-cancer activity that can be safely strengthened and precisely targeted through our proprietary genetic programming technologies. Oncolytic MV is administered either intratumorally or intravesically. For patients with high anti-measles antibody levels, MV may be administered via carrier cells that transport the treatment to tumor sites without detection of pre-existing anti-measles immunity. Measles is a fusogenic virus that utilizes diverse cancer killing mechanisms which may trigger robust anti-cancer immune activity.
Learn MoreClinical Development
Multiple Phase 1-2 clinical trials are underway using Vyriad’s lead clinical asset, Voyager-V1, an armed and trackable oncolytic VSV, in combination with immune modulating drugs. Indications include metastatic colorectal cancer (Voyager-V1 in combination with avelumab, an anti-PD-L1 antibody from Merck KGaA/Pfizer), non-small cell lung cancer and head and neck cancer (Voyager-V1 plus pembrolizumab), endometrial cancer and hematological malignancies (Voyager-V1 with ruxolitinib). A Phase 2 study will soon commence in collaboration with Regeneron Pharmaceuticals in melanoma, lung, liver and endometrial cancers (Voyager-V1 with cemiplimab, Regeneron’s anti-PD1 antibody). Clinical studies with Vyriad’s second oncolytic virus platform, an engineered measles virus, are ongoing in bladder cancer and recurrent brain cancers (medulloblastoma and Atypical Teratoid Rhabdoid Tumor). For more information, including patient enrollment and eligibility, please see our Clinical Program.